Search
eribulin mesylate (Halaven)
Indications:
- FDA-approved for treatment of metastatic breast cancer, intended for patients who have already received at least two regimens of chemotherapy for late-stage disease [1]
Contraindications:
- not recommended for treatment of metastatic breast cancer [3]
Dosage: injection
Adverse effects:
- leukopenia (neutropenia) 82%
- anemia (58%)
- weakness/tiredness (54%)
- alopecia (45%)
- parestheaia (35%)
- nausea (35%)
- constipation (25%)
Mechanism of action:
- binds predominantly to a small number of high affinity sites at the plus ends of existing microtubules
- inhibits microtubule dynamics & thus mitosis
- triggers apoptosis of cancer cells following prolonged & irreversible mitotic blockade [2]
General
antineoplastic agent (chemotherapeutic agent)
References
- FDA News Release: Nov. 15, 2010
FDA approves new treatment option for late-stage breast cancer
http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm233863.htm
- Wikipedia: Eribulin
http://en.wikipedia.org/wiki/Eribulin
- Havalen (eribulin mesylate) injection
http://www.halaven.com/patients.aspx